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Introduction {#add14944-sec-0005}
============

The Middle East and North Africa (MENA) region is reported to have the highest prevalence of hepatitis C virus (HCV) infection globally, with approximately 20% of all chronically infected individuals residing in MENA [1](#add14944-bib-0001){ref-type="ref"}, [2](#add14944-bib-0002){ref-type="ref"}. Chronic HCV infection may lead to several morbidities, such as liver fibrosis, cancer and cirrhosis [3](#add14944-bib-0003){ref-type="ref"}, placing a burden on health‐care systems [4](#add14944-bib-0004){ref-type="ref"}. Recent development of the highly effective direct‐acting antivirals (DAA) provides promising new opportunities in controlling HCV transmission and its disease burden [5](#add14944-bib-0005){ref-type="ref"}. As such, a global target for elimination of HCV infection by 2030 has been set by the World Health Organization (WHO) [6](#add14944-bib-0006){ref-type="ref"}, [7](#add14944-bib-0007){ref-type="ref"}.

HCV is a blood‐borne pathogen that is transmitted predominantly parenterally [3](#add14944-bib-0003){ref-type="ref"}. As a consequence of practices such as sharing of needles and/or syringes, people who inject drugs (PWID) are a key population at high risk of HCV infection, half of whom are estimated to have been infected with HCV globally [8](#add14944-bib-0008){ref-type="ref"}. MENA is particularly vulnerable to injecting drug use, being at the epicenter of major drug production sites and trade routes [9](#add14944-bib-0009){ref-type="ref"}, [10](#add14944-bib-0010){ref-type="ref"}. Recent evidence has suggested that targeting PWID for HCV screening is critical for program efficiency in identifying HCV infections [11](#add14944-bib-0011){ref-type="ref"}. A comprehensive characterization of HCV epidemiology in PWID in this region is essential to inform the expansion of harm reduction services and development of population‐specific and cost‐effective screening and treatment programs for HCV infection.

The aim of this study was to delineate HCV epidemiology among PWID in MENA by: (1) estimating the country‐specific pooled mean HCV antibody prevalence in PWID, (2) estimating the country‐specific number of chronically infected PWID, (3) identifying predictors and trends of HCV antibody prevalence in PWID as well as sources of between‐study heterogeneity and (4) estimating the pooled mean proportions and diversity of HCV genotypes in PWID. This study was conducted as part of the MENA HCV Epidemiology Synthesis Project [2](#add14944-bib-0002){ref-type="ref"}, an ongoing undertaking to characterize HCV epidemiology and inform key public health research, policy and programming priorities in the region.

Methods {#add14944-sec-0006}
=======

Data sources {#add14944-sec-0007}
------------

All studies reporting on HCV measures in PWID in MENA were retrieved from the MENA HCV Epidemiology Synthesis Project database [2](#add14944-bib-0002){ref-type="ref"}. This comprehensive database includes several subdatabases, such as an HCV antibody prevalence subdatabase comprised of 2614 antibody prevalence studies among 49 821 739 participants, an HCV genotype frequency subdatabase comprised of 338 HCV genotype studies among 82 257 participants and an HCV ribonucleic acid (RNA) prevalence (among antibody‐positive people) subdatabase comprised of 179 RNA prevalence studies among 19 680 participants.

The Synthesis Project database was developed through a series of systematic reviews for HCV infection throughout MENA [12](#add14944-bib-0012){ref-type="ref"}, [13](#add14944-bib-0013){ref-type="ref"}, [14](#add14944-bib-0014){ref-type="ref"}, [15](#add14944-bib-0015){ref-type="ref"}, [16](#add14944-bib-0016){ref-type="ref"}, [17](#add14944-bib-0017){ref-type="ref"}, [18](#add14944-bib-0018){ref-type="ref"}, [19](#add14944-bib-0019){ref-type="ref"}. Additional data in PWID were searched for by performing a search update of PubMed and Embase, following similar methodologies to these systematic reviews [12](#add14944-bib-0012){ref-type="ref"}, [13](#add14944-bib-0013){ref-type="ref"}, [14](#add14944-bib-0014){ref-type="ref"}, [15](#add14944-bib-0015){ref-type="ref"}, [16](#add14944-bib-0016){ref-type="ref"}, [17](#add14944-bib-0017){ref-type="ref"}, [18](#add14944-bib-0018){ref-type="ref"}, [19](#add14944-bib-0019){ref-type="ref"}. In brief, to perform the update, all records reporting HCV antibody prevalence and/or incidence in PWID in MENA up to November 2018 were systematically reviewed and included in this study, as informed by the Cochrane Collaboration handbook [20](#add14944-bib-0020){ref-type="ref"}, and reported using the Preferred Reporting Items for Systematic reviews and Meta‐analyses (PRISMA) guidelines ([Supporting information, Table S1](#add14944-supitem-0001){ref-type="supplementary-material"}). Broad search criteria with no language restrictions were used in all these reviews ([Supporting information, Fig. S1](#add14944-supitem-0001){ref-type="supplementary-material"} **)** [12](#add14944-bib-0012){ref-type="ref"}, [13](#add14944-bib-0013){ref-type="ref"}, [14](#add14944-bib-0014){ref-type="ref"}, [15](#add14944-bib-0015){ref-type="ref"}, [16](#add14944-bib-0016){ref-type="ref"}, [17](#add14944-bib-0017){ref-type="ref"}, [18](#add14944-bib-0018){ref-type="ref"}, [19](#add14944-bib-0019){ref-type="ref"}. All records reporting HCV measures after 1989, the year in which existence of HCV as a virus was established [21](#add14944-bib-0021){ref-type="ref"}, [22](#add14944-bib-0022){ref-type="ref"}, were included in these reviews [12](#add14944-bib-0012){ref-type="ref"}, [13](#add14944-bib-0013){ref-type="ref"}, [14](#add14944-bib-0014){ref-type="ref"}, [15](#add14944-bib-0015){ref-type="ref"}, [16](#add14944-bib-0016){ref-type="ref"}, [17](#add14944-bib-0017){ref-type="ref"}, [18](#add14944-bib-0018){ref-type="ref"}, [19](#add14944-bib-0019){ref-type="ref"}.

All data included in the reviews [12](#add14944-bib-0012){ref-type="ref"}, [13](#add14944-bib-0013){ref-type="ref"}, [14](#add14944-bib-0014){ref-type="ref"}, [15](#add14944-bib-0015){ref-type="ref"}, [16](#add14944-bib-0016){ref-type="ref"}, [17](#add14944-bib-0017){ref-type="ref"}, [18](#add14944-bib-0018){ref-type="ref"}, [19](#add14944-bib-0019){ref-type="ref"} were identified through literature searches using international databases (PubMed and Embase), regional and country‐level databases (WHO Index Medicus for the Eastern Mediterranean Region and the Iraqi Academic Scientific Journals, Iran\'s Scientific Information, among others), MENA HIV/AIDS Epidemiology Synthesis Project database [23](#add14944-bib-0023){ref-type="ref"}, [24](#add14944-bib-0024){ref-type="ref"}, abstract archives of non‐indexed international conferences and gray literature comprised of public health reports and routine data reporting.

Duplicate records were excluded and the remaining unique records underwent two rounds of screening. The titles and abstracts were screened for relevance, and full texts of potentially relevant records were retrieved and further screened. References of all included full texts were also screened for additional data that may have been missed. Any document reporting primary data on HCV antibody prevalence and/or incidence was included. All records were included in an additional independent screening for HCV genotype information, regardless of whether or not they had reported HCV antibody prevalence.

In this study, MENA consists of 24 countries: Afghanistan, Algeria, Bahrain, Djibouti, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Mauritania, Morocco, Oman, Pakistan, Palestine, Qatar, Saudi Arabia, Somalia, Sudan, Syria, Tunisia, the United Arab Emirates (UAE) and Yemen.

The analysis in this study was not pre‐registered and the results should be considered exploratory.

Pooled mean HCV antibody prevalence {#add14944-sec-0008}
-----------------------------------

Country‐specific meta‐analyses to pool HCV antibody prevalence measures were performed whenever three or more prevalence measures were available, with a minimum sample size of 25 participants for each measure. HCV antibody prevalence for the total sample was replaced with stratified measures if the sample size requirement was held for each stratum. Only one stratification level for each study was included based on an a priori sequential order of prioritizing nationality followed by sex, year and age.

All meta‐analyses were performed using DerSimonian--Laird random‐effects models with inverse variance weighting to pool measures [25](#add14944-bib-0025){ref-type="ref"}. Variance of each measure was stabilized using the Freeman--Tukey‐type arcsine square root transformation [26](#add14944-bib-0026){ref-type="ref"}. Heterogeneity was characterized using several statistical measures [25](#add14944-bib-0025){ref-type="ref"}, [27](#add14944-bib-0027){ref-type="ref"}. Forest plots were visually inspected and Cochran\'s Q‐test was conducted, where a *P*‐value \< 0.10 was considered to indicate statistical significance [25](#add14944-bib-0025){ref-type="ref"}, [27](#add14944-bib-0027){ref-type="ref"}, *I* ^2^ and its confidence interval (CI) were calculated [25](#add14944-bib-0025){ref-type="ref"}. Prediction intervals were also calculated to discern the distribution of true effects around the estimated mean [25](#add14944-bib-0025){ref-type="ref"}, [28](#add14944-bib-0028){ref-type="ref"}.

Statistical analyses were performed using R version 3.4.3 [29](#add14944-bib-0029){ref-type="ref"}.

Estimation of number of HCV‐infected PWID {#add14944-sec-0009}
-----------------------------------------

The country‐specific number of HCV antibody‐positive PWID was calculated by multiplying the country‐specific pooled HCV antibody prevalence by the country‐specific population size of PWID. If the country‐specific pooled HCV antibody prevalence was unavailable, the pooled HCV antibody prevalence for MENA as a whole was used. This was subsequently multiplied by the region\'s pooled mean fraction of HCV RNA positivity among antibody‐positive PWID (i.e. the 'viremic rate' [30](#add14944-bib-0030){ref-type="ref"}, [31](#add14944-bib-0031){ref-type="ref"}) to attain the number of chronically infected PWID in each country and in MENA as a whole.

The viremic rate was estimated by performing a meta‐analysis of proportion for all HCV RNA positivity data among antibody‐positive PWID in MENA. The country‐specific population size of PWID was derived from a systematic review and synthesis in which PWID population proportion and population size were extracted and synthesized from publications in the peer‐reviewed literature, United Nations Office on Drugs and Crime (UNODC) estimates and data provided by the WHO Eastern Mediterranean Regional Office (EMRO) [32](#add14944-bib-0032){ref-type="ref"}. In countries with multiple population‐size estimates, the median of these estimates was used. The estimates were subsequently updated with recent data [33](#add14944-bib-0033){ref-type="ref"}, [34](#add14944-bib-0034){ref-type="ref"}, [35](#add14944-bib-0035){ref-type="ref"}, [36](#add14944-bib-0036){ref-type="ref"}, [37](#add14944-bib-0037){ref-type="ref"}, [38](#add14944-bib-0038){ref-type="ref"}, [39](#add14944-bib-0039){ref-type="ref"}, [40](#add14944-bib-0040){ref-type="ref"}, [41](#add14944-bib-0041){ref-type="ref"}, [42](#add14944-bib-0042){ref-type="ref"} identified through a data and literature search.

Predictors, trends and sources of between‐study heterogeneity for HCV antibody prevalence {#add14944-sec-0010}
-----------------------------------------------------------------------------------------

Based on established methodology, [20](#add14944-bib-0020){ref-type="ref"} univariable and multivariable random‐effects meta‐regressions were performed to assess the predictors of HCV antibody prevalence in PWID, trend in prevalence over time and sources of between‐study heterogeneity. A priori‐relevant independent variables included country, study site, year of data collection and year of publication (to assess trend in HCV antibody prevalence over time), sample size (\< 100 or ≥ 100) and sampling method (probability‐based versus non‐probability‐based). Countries with three or fewer studies were lumped together as one category referred to as 'Others'. Variables with a likelihood ratio test *P*‐value of \< 0.20 in the univariable analysis were included in the final multivariable model. Variables with a *P*‐value of \< 0.05 in the multivariable model were deemed statistically significant.

In studies where the year of data collection variable was unavailable, missing observations were imputed. This was performed by using the median of the values calculated by subtracting the year of data collection from the year of publication for each study.

Separate meta‐regressions were performed in countries with ≥ 15 studies to assess the trend in HCV antibody prevalence over time.

Meta‐regressions were performed on Stata version 13, using the metan command [43](#add14944-bib-0043){ref-type="ref"}.

Genotype proportions and diversity {#add14944-sec-0011}
----------------------------------

Individuals with untypeable genotypes were removed from the sample size of each study. Individuals with mixed genotypes contributed separately to the enumeration of each genotype. Frequency of each genotype was calculated. The pooled mean proportion for each genotype and the corresponding 95% CI were also estimated by performing random‐effects meta‐analyses. Diversity of genotypes was assessed by calculating the Shannon Diversity Index, with higher score indicating higher diversity [44](#add14944-bib-0044){ref-type="ref"}. Assuming highest diversity, i.e. equal distribution among the seven main genotypes [44](#add14944-bib-0044){ref-type="ref"}, the largest Shannon Diversity Index score possible is 1.95 [45](#add14944-bib-0045){ref-type="ref"}.

Results {#add14944-sec-0012}
=======

Overview of evidence {#add14944-sec-0013}
--------------------

Supporting information, Figs [S2](#add14944-supitem-0001){ref-type="supplementary-material"} and [S3](#add14944-supitem-0001){ref-type="supplementary-material"} outline the process by which HCV incidence and/or prevalence studies and HCV genotype studies were selected in the update, as per the PRISMA flow diagram. Relative to the previous systematic reviews, the update identified no additional incidence reports, 10 additional prevalence reports and one additional genotype report.

Results using all searches combined were generated based on analysis of 118 HCV antibody measures among a total of 46 493 PWID (Table [1](#add14944-tbl-0001){ref-type="table"}), seven HCV RNA positivity measures among a total of 920 antibody‐positive PWID (Supporting information, Table [S2](#add14944-supitem-0001){ref-type="supplementary-material"}) and 15 genotype frequency measures among a total of 969 HCV RNA‐positive PWID (Supporting information, Table [S3](#add14944-supitem-0001){ref-type="supplementary-material"}).

###### 

Studies reporting hepatitis C virus (HCV) antibody prevalence among people who inject drugs (PWID) across the Middle East and North Africa (MENA).

  Author, year (citation)                                                                                                            Year(s) of data collection   Study site                           Study design                                 Study sampling procedure       Sample size   HCV antibody prevalence (%)
  ---------------------------------------------------------------------------------------------------------------------------------- ---------------------------- ------------------------------------ -------------------------------------------- ------------------------------ ------------- -----------------------------
  Afghanistan (*n* = 17)                                                                                                                                                                                                                                                                         
  Afghanistan NACP, 2010 [46](#add14944-bib-0046){ref-type="ref"}                                                                    2009                         NS                                   CS                                           RDS                            286           37.1
  Afghanistan NACP, 2010 [46](#add14944-bib-0046){ref-type="ref"}                                                                    2009                         NS                                   CS                                           RDS                            159           57.9
  Afghanistan NACP, 2010 [46](#add14944-bib-0046){ref-type="ref"}                                                                    2009                         NS                                   CS                                           RDS                            102           25.5
  Afghanistan NACP, 2012 [47](#add14944-bib-0047){ref-type="ref"}                                                                    2012                         NS                                   CS                                           RDS                            369           27.6
  Afghanistan NACP, 2012 [47](#add14944-bib-0047){ref-type="ref"}                                                                    2012                         NS                                   CS                                           RDS                            185           70.8
  Afghanistan NACP, 2012 [47](#add14944-bib-0047){ref-type="ref"}                                                                    2012                         NS                                   CS                                           RDS                            254           23.6
  Afghanistan NACP, 2012 [47](#add14944-bib-0047){ref-type="ref"}                                                                    2012                         NS                                   CS                                           RDS                            236           15.3
  Afghanistan NACP, 2012 [47](#add14944-bib-0047){ref-type="ref"}                                                                    2012                         NS                                   CS                                           RDS                            117           28.2
  Bautista, 2010 [48](#add14944-bib-0048){ref-type="ref"}                                                                            2005--06                     VCT                                  CS                                           Conv                           153           36.0
  Bautista, 2010 [48](#add14944-bib-0048){ref-type="ref"}                                                                            2005--06                     VCT                                  CS                                           Conv                           159           37.0
  Bautista, 2010 [48](#add14944-bib-0048){ref-type="ref"}                                                                            2005--06                     VCT                                  CS                                           Conv                           147           37.0
  MENA HIV Epidemiology Synthesis Project, 2011 [23](#add14944-bib-0023){ref-type="ref"}, [49](#add14944-bib-0049){ref-type="ref"}   2011                         NS                                   CS                                           NS                             4866          15.7
  Nasir, 2011 [50](#add14944-bib-0050){ref-type="ref"}                                                                               2006--08                     VCT                                  CS                                           Conv                           340           49.1
  Nasir, 2011 [50](#add14944-bib-0050){ref-type="ref"}                                                                               2006--08                     VCT                                  CS                                           Conv                           96            12.5
  Nasir, 2011 [50](#add14944-bib-0050){ref-type="ref"}                                                                               2006--8                      VCT                                  CS                                           Conv                           187           24.1
  Todd, 2007 [51](#add14944-bib-0051){ref-type="ref"}                                                                                2005--06                     VCT                                  CS                                           Conv                           458           36.9
  Todd, 2011 [52](#add14944-bib-0052){ref-type="ref"}                                                                                2007--09                     NS                                   CS                                           Conv                           483           36.1
  Egypt (*n* = 2)                                                                                                                                                                                                                                                                                
  el‐Ghazzawi, 1995 [53](#add14944-bib-0053){ref-type="ref"}                                                                         NS                           NS                                   CC                                           Conv                           100           63.0
  Mohsen, 2015 [54](#add14944-bib-0054){ref-type="ref"}                                                                              2002--12                     Clinical setting                     CC                                           Conv                           143           40.6
  Iran (*n* = 60)                                                                                                                                                                                                                                                                                
  Abadi, 2018 [55](#add14944-bib-0055){ref-type="ref"}                                                                               2013--14                     Clinical setting                     CS                                           Conv                           173           53.5
  Alavi, 2007 [56](#add14944-bib-0056){ref-type="ref"}                                                                               2001--03                     Clinical setting                     CS                                           Conv                           104           74.0
  Alavi, 2009 [57](#add14944-bib-0057){ref-type="ref"}                                                                               2001--06                     Clinical setting                     CS                                           Conv                           142           52.1
  Alipour, 2013 [58](#add14944-bib-0058){ref-type="ref"}                                                                             NS                           Drop‐in or rehabilitation center     CS                                           Conv                           42            35.7
  Alipour, 2013 [58](#add14944-bib-0058){ref-type="ref"}                                                                             NS                           Drop‐in or rehabilitation center     CS                                           Conv                           226           38.1
  Alizadeh, 2005 [59](#add14944-bib-0059){ref-type="ref"}                                                                            2002                         Prison                               CS                                           SRS                            149           31.5
  Amini, 2005 [60](#add14944-bib-0060){ref-type="ref"}                                                                               NS                           Blood transfusion center             CS                                           Conv                           34            64.7
  Amiri, 2007 [61](#add14944-bib-0061){ref-type="ref"}                                                                               2003                         Prison                               CS                                           Conv                           81            88.9
  Asl, 2013 [62](#add14944-bib-0062){ref-type="ref"}                                                                                 2003--5                      Prison                               Coh[a](#add14944-note-0002){ref-type="fn"}   Conv                           150           69.3
  Ataei, 2010 [63](#add14944-bib-0063){ref-type="ref"}                                                                               2008--09                     Drop‐in or rehabilitation center     CS                                           Conv                           3284          38.0
  Ataei, 2011 [64](#add14944-bib-0064){ref-type="ref"}                                                                               NS                           Prison                               CS                                           Conv                           1485          43.4
  Ataei, 2011 [65](#add14944-bib-0065){ref-type="ref"}                                                                               NS                           Drop‐in or rehabilitation center     CS                                           Conv                           136           19.9
  Davoodian, 2009 [66](#add14944-bib-0066){ref-type="ref"}                                                                           2002                         Prison                               CS                                           SRS                            249           65.5
  Doosti‐Irani, 2017 [67](#add14944-bib-0067){ref-type="ref"}                                                                        2015                         Community                            CS                                           Conv                           119           80.7
  Eskandarieh, 2013 [68](#add14944-bib-0068){ref-type="ref"}                                                                         NS                           Drop‐in or rehabilitation center     CS                                           Conv                           258           65.1
  Honarvar, 2013 [69](#add14944-bib-0069){ref-type="ref"}                                                                            2012--13                     Drop‐in and rehabilitation centers   CS                                           Conv                           233           40.3
  Hosseini, 2010 [70](#add14944-bib-0070){ref-type="ref"}                                                                            2006                         Prison                               CS                                           Conv                           417           80.1
  Imani, 2008 [71](#add14944-bib-0071){ref-type="ref"}                                                                               2004                         Drop‐in or rehabilitation center     CS                                           Conv                           133           11.3
  Ismail, 2005 [72](#add14944-bib-0072){ref-type="ref"}                                                                              NS                           Clinical setting                     CS                                           Conv                           65            16.9
  Kaffashian, 2011 [73](#add14944-bib-0073){ref-type="ref"}                                                                          NS                           Prison                               CS                                           Conv                           951           41.9
  Kassaian, 2012 [74](#add14944-bib-0074){ref-type="ref"}                                                                            2009                         Prison                               CS                                           Conv                           943           41.6
  Keramat, 2011 [75](#add14944-bib-0075){ref-type="ref"}                                                                             2005--07                     Drop‐in or rehabilitation center     CS                                           Conv                           199           63.3
  Khani, 2003 [76](#add14944-bib-0076){ref-type="ref"}                                                                               2001                         Prison                               CS                                           Conv                           346           50.9
  Kheirandish, 2009 [77](#add14944-bib-0077){ref-type="ref"}                                                                         2006                         Prison                               CS                                           Conv                           61            67.2
  Kheirandish, 2009 [77](#add14944-bib-0077){ref-type="ref"}                                                                         2006                         Prison                               CS                                           Conv                           229           80.8
  Kheirandish, 2009 [77](#add14944-bib-0077){ref-type="ref"}                                                                         2006                         Prison                               CS                                           Conv                           103           82.5
  Kheirandish, 2009 [77](#add14944-bib-0077){ref-type="ref"}                                                                         2006                         Prison                               CS                                           Conv                           49            87.8
  Khorvash, 2008 [78](#add14944-bib-0078){ref-type="ref"}                                                                            2005                         Clinical setting                     CS                                           Conv                           92            71.0
  Mehrjerdi, 2014 [79](#add14944-bib-0079){ref-type="ref"}                                                                           2011                         Drop‐in or rehabilitation center     CS                                           Conv                           209           26.8
  Meydani, 2009 [80](#add14944-bib-0080){ref-type="ref"}                                                                             2007--08                     Clinical setting                     CS                                           Conv                           150           26.0
  Mirahmadizadeh, 2004 [81](#add14944-bib-0081){ref-type="ref"}                                                                      NS                           NS                                   CS                                           Conv                           186           80.1
  Mirahmadizadeh, 2009 [82](#add14944-bib-0082){ref-type="ref"}                                                                      NS                           Drop‐in or rehabilitation center     CS                                           SRS                            936           43.4
  Mir‐Nasseri, 2005 [83](#add14944-bib-0083){ref-type="ref"}                                                                         2001--02                     Drop‐in or rehabilitation center     CS                                           NS                             42            50.0
  Mir‐Nasseri, 2005 [83](#add14944-bib-0083){ref-type="ref"}                                                                         2001--02                     Drop‐in or rehabilitation center     CS                                           NS                             425           67.5
  Mir‐Nasseri, 2008 [84](#add14944-bib-0084){ref-type="ref"}                                                                         2001--02                     Drop‐in or rehabilitation center     CS                                           Conv                           54            38.9
  Mir‐Nasseri, 2008 [84](#add14944-bib-0084){ref-type="ref"}                                                                         2001--02                     Drop‐in or rehabilitation center     CS                                           Conv                           464           61.9
  Mir‐Nasseri, 2011 [85](#add14944-bib-0085){ref-type="ref"}                                                                         2001--02                     Drop‐in or rehabilitation center     CS                                           Conv                           518           69.3
  Moradi, 2018 [86](#add14944-bib-0086){ref-type="ref"}                                                                              2015                         Prison                               CS                                           Multi‐stage cluster sampling   678           42.5
  Momen‐Heravi, 2012 [87](#add14944-bib-0087){ref-type="ref"}                                                                        NS                           Drop‐in or rehabilitation center     CS                                           Multi‐stage cluster sampling   300           47.3
  Pourahmad, 2007 [88](#add14944-bib-0088){ref-type="ref"}                                                                           2003                         Prison                               CC                                           Conv                           401           76.8
  Rahbar, 2004 [89](#add14944-bib-0089){ref-type="ref"}                                                                              2001                         Prison                               CC                                           Conv                           101           59.4
  Rahimi‐Movaghar, 2010 [90](#add14944-bib-0090){ref-type="ref"}                                                                     2006--07                     Drop‐in or rehabilitation center     CS                                           Snowball sampling              859           34.1
  Rahimi‐Movaghar, 2010 [90](#add14944-bib-0090){ref-type="ref"}                                                                     2006--07                     Drop‐in or rehabilitation center     CS                                           Snowball sampling              36            44.4
  Ramezani, 2014 [91](#add14944-bib-0091){ref-type="ref"}                                                                            2012                         Drop‐in or rehabilitation center     CS                                           Conv                           100           56.0
  Rostami‐Jalilian, 2006 [92](#add14944-bib-0092){ref-type="ref"}                                                                    2002--04                     Clinical setting                     CS                                           Conv                           76            34.2
  Rostami‐Jalilian, 2006 [92](#add14944-bib-0092){ref-type="ref"}                                                                    2002--04                     Clinical setting                     CS                                           Conv                           72            45.8
  Saleh, 2011 [93](#add14944-bib-0093){ref-type="ref"}                                                                               2007--08                     Clinical setting                     CC                                           Conv                           94            60.6
  Salehi, 2015 [94](#add14944-bib-0094){ref-type="ref"}                                                                              2006--11                     Community                            CS                                           Conv                           1327          13.5
  Sarkari, 2012 [96](#add14944-bib-0096){ref-type="ref"}                                                                             2009--10                     NS                                   CS                                           Conv                           158           42.4
  Shahrani, 2017 [97](#add14944-bib-0097){ref-type="ref"}                                                                            2017                         Drop‐in or rehabilitation center     CS                                           Snowball sampling              606           54.8
  Sharif, 2009 [98](#add14944-bib-0098){ref-type="ref"}                                                                              2001--06                     Clinical setting                     CS                                           Conv                           200           12.0
  Sharifi‐Mood, 2006 [99](#add14944-bib-0099){ref-type="ref"}                                                                        2000--05                     Clinical setting                     CS                                           Conv                           31            22.6
  Sofian, 2012 [100](#add14944-bib-0100){ref-type="ref"}                                                                             2009                         Prison                               CS                                           Conv                           153           59.5
  Soudbakhsh, 2008 [101](#add14944-bib-00101){ref-type="ref"}                                                                        NS                           Clinical setting                     CS                                           Conv                           26            88.5
  Tavanaee, 2012 [95](#add14944-bib-0095){ref-type="ref"}                                                                            2007--09                     Clinical setting                     CS                                           Conv                           62            71.0
  Tayeri, 2008 [102](#add14944-bib-0101){ref-type="ref"}                                                                             2000--07                     Clinical setting                     CS                                           Conv                           106           75.5
  Aminzadeh, 2007 [103](#add14944-bib-0102){ref-type="ref"}                                                                          2007                         NS                                   CS                                           Conv                           70            35.7
  Zali, 2001 [104](#add14944-bib-0103){ref-type="ref"}                                                                               1995                         Prison                               CS                                           SRS                            402           45.3
  Zamani, 2007 [105](#add14944-bib-0104){ref-type="ref"}                                                                             2004                         Mixed                                CS                                           Conv                           202           52.0
  Zamani, 2010 [106](#add14944-bib-0105){ref-type="ref"}                                                                             2008                         Drop‐in or rehabilitation center     CS                                           Snowball sampling              117           60.7
  Lebanon (*n* = 3)                                                                                                                                                                                                                                                                              
  Mahfoud, 2010 [107](#add14944-bib-0106){ref-type="ref"}                                                                            2007--08                     NS                                   CS                                           RDS                            106           52.8
  Merabi, 2016 [108](#add14944-bib-0107){ref-type="ref"}                                                                             2013                         Drop‐in or rehabilitation center     CS                                           Conv                           94            23.4
  Ramia, 2003 [109](#add14944-bib-0108){ref-type="ref"}                                                                              NS                           Clinical setting                     CS                                           Conv                           40            5.0
  Libya (*n* = 1)                                                                                                                                                                                                                                                                                
  Mirzoyan, 2013 [110](#add14944-bib-0109){ref-type="ref"}                                                                           2010--10                     Community                            CS                                           RDS                            328           94.2
  Morocco (*n* = 3)                                                                                                                                                                                                                                                                              
  Integrated behavioral and biological survey, 2012 [111](#add14944-bib-0110){ref-type="ref"}                                        NS                           NS                                   CS                                           RDS                            269           45.6
  Integrated behavioral and biological survey, 2012 [111](#add14944-bib-0110){ref-type="ref"}                                        NS                           NS                                   CS                                           RDS                            278           79.2
  Moroccan Ministry of Health, 2014 [112](#add14944-bib-0111){ref-type="ref"}                                                        2013--14                     NS                                   CS                                           RDS                            212           45.4
  Oman (*n* = 1)                                                                                                                                                                                                                                                                                 
  EMRO, 2011 [113](#add14944-bib-0112){ref-type="ref"}                                                                               NS                           NS                                   CS                                           Conv                           512           48.1
  Pakistan (*n* = 19)                                                                                                                                                                                                                                                                            
  Kuo, 2006 [114](#add14944-bib-0113){ref-type="ref"}                                                                                2003--03                     Clinical setting                     CS                                           Conv                           351           88.0
  Achakzai, 2007 [115](#add14944-bib-0114){ref-type="ref"}                                                                           2004                         Community                            CS                                           Conv                           50            60.0
  Altaf, 2007 [116](#add14944-bib-0115){ref-type="ref"}                                                                              2003                         Drop‐in or rehabilitation center     CS                                           Conv                           161           94.3
  Abbasi, 2009 [117](#add14944-bib-0116){ref-type="ref"}                                                                             2003                         Community                            CS                                           Conv                           300           44.7
  Butt, 2011 [118](#add14944-bib-0117){ref-type="ref"}                                                                               NS                           Prison                               CS                                           Conv                           76            84.2
  Platt, 2009 [119](#add14944-bib-0118){ref-type="ref"}                                                                              2007                         Community                            CS                                           RDS                            302           17.3
  Platt, 2009 [119](#add14944-bib-0118){ref-type="ref"}                                                                              2007                         Community                            CS                                           RDS                            102           8.0
  Rehan, 2009 [120](#add14944-bib-0119){ref-type="ref"}                                                                              2004                         Community                            CS                                           SRS                            399           87.0
  Rehan, 2009 [120](#add14944-bib-0119){ref-type="ref"}                                                                              2004                         Community                            CS                                           SRS                            380           91.8
  Rehman, 2011 [121](#add14944-bib-0120){ref-type="ref"}                                                                             NS                           Community                            CS                                           Conv                           100           35.0
  Rehman, 2011 [121](#add14944-bib-0120){ref-type="ref"}                                                                             NS                           Community                            CS                                           Conv                           60            25.0
  Rehman, 2011 [121](#add14944-bib-0120){ref-type="ref"}                                                                             NS                           Community                            CS                                           Conv                           40            32.5
  Memon, 2012 [122](#add14944-bib-0121){ref-type="ref"}                                                                              2007--08                     Laboratory                           CS                                           Conv                           407           68.3
  Daud, 2014 [123](#add14944-bib-0122){ref-type="ref"}                                                                               2008                         Drop‐in or rehabilitation center     CS                                           Conv                           81            77.8
  Akhtar, 2016 [124](#add14944-bib-0123){ref-type="ref"}                                                                             2012--13                     Community                            CS                                           Conv                           241           36.1
  Mansha, 2017 [125](#add14944-bib-0124){ref-type="ref"}                                                                             2013                         Laboratory                           CS                                           Conv                           100           55.0
  Waheed, 2017 [126](#add14944-bib-0125){ref-type="ref"}                                                                             2016                         Community                            CS                                           Conv                           72            83.3
  Ali, 2011 [127](#add14944-bib-0126){ref-type="ref"}                                                                                NS                           Mixed                                CS                                           Conv                           42            14.3
  Rasool, 2014 [128](#add14944-bib-0127){ref-type="ref"}                                                                             2009                         Clinical setting                     Coh[a](#add14944-note-0002){ref-type="fn"}   Conv                           40            42.0
  Palestine (*n* = 4)                                                                                                                                                                                                                                                                            
  Stulhofer, 2012 [129](#add14944-bib-0128){ref-type="ref"}                                                                          2010                         Other                                CS                                           RDS                            192           43.8
  Stulhofer, 2016 [130](#add14944-bib-0129){ref-type="ref"}                                                                          2013                         NS                                   CS                                           TLS                            100           39.0
  Stulhofer, 2016 [130](#add14944-bib-0129){ref-type="ref"}                                                                          2013                         NS                                   CS                                           TLS                            83            33.7
  Stulhofer, 2016 [130](#add14944-bib-0129){ref-type="ref"}                                                                          2013                         NS                                   CS                                           TLS                            105           47.6
  Saudi Arabia (*n* = 5)                                                                                                                                                                                                                                                                         
  Njoh, 1997 [131](#add14944-bib-0130){ref-type="ref"}                                                                               1995--96                     Drop‐in or rehabilitation center     CS                                           Conv                           1909          74.6
  Iqbal, 2000 [132](#add14944-bib-0131){ref-type="ref"}                                                                              NS                           Clinical setting                     CS                                           Conv                           574           69.0
  Shobokshi, 2003 [133](#add14944-bib-0132){ref-type="ref"}                                                                          1998--2002                   Clinical setting                     CS                                           Conv                           9137          14.4
  Alshomrani, 2015 [134](#add14944-bib-0133){ref-type="ref"}                                                                         2006--12                     Clinical setting                     CS                                           Conv                           378           77.8
  Alibrahim, 2018 [135](#add14944-bib-0134){ref-type="ref"}                                                                          2012                         Drop‐in or rehabilitation center     CS                                           Conv                           300           42.7
  Syria (*n* = 2)                                                                                                                                                                                                                                                                                
  Syrian Ministry of Health, 2008 [136](#add14944-bib-0135){ref-type="ref"}                                                          2006                         NS                                   CS                                           Snowball sampling              57            21.0
  Othman, 2002 [137](#add14944-bib-0136){ref-type="ref"}                                                                             NS                           NS                                   CS                                           Conv                           38            60.5
  Tunisia (*n* = 1)                                                                                                                                                                                                                                                                              
  Belarbi, 2013 [138](#add14944-bib-0137){ref-type="ref"}                                                                            2012                         Clinical setting                     CS                                           Conv                           23            21.7

NACP = National AIDS Control Program; EMRO = Eastern Mediterranean Regional Office; NS = not specified; VCT = voluntary counselling and testing; CS = cross‐sectional; CC = case--control; Coh = cohort; RDS = respondent‐driven sampling; Conv = convenience; SRS = simple random sampling; TLS = time--location sampling.

In cohort studies the extracted HCV antibody prevalence measure was the cross‐sectional baseline HCV antibody prevalence measure.

PWID data were available for 12 of the 24 MENA countries. No studies were available for Algeria, Bahrain, Djibouti, Iraq, Jordan, Kuwait, Mauritania, Qatar, Somalia, Sudan, UAE and Yemen. Iran contributed the largest number of data points of HCV antibody prevalence measures (*n* = 60), followed by Pakistan (*n* = 19). HCV RNA positivity measures were available for only four countries: Afghanistan, Iran, Lebanon and Pakistan. Genotype frequency measures were available for only seven countries: Afghanistan, Iran, Lebanon, Morocco, Pakistan and Saudi Arabia.

Studies identified their samples from various study sites, such as in the community (a geographical area, such as a city, town, village, etc.), clinical setting (such as a hospital), drop‐in center or rehabilitation center, voluntary counselling and testing center, prison or were not specified. The majority of studies used non‐probability‐based sampling (approximately 75%) to recruit study subjects, and had a sample size ≥ 100 (approximately 70%).

HCV antibody prevalence among PWID {#add14944-sec-0014}
----------------------------------

HCV antibody prevalence ranged from 5.0% in a study from Lebanon [109](#add14944-bib-0108){ref-type="ref"} to 94.3% in a study from Pakistan [116](#add14944-bib-0115){ref-type="ref"} (Table [1](#add14944-tbl-0001){ref-type="table"}). The median HCV antibody prevalence among all studies was 45.5%, with an interquartile range of 34.4--67.4%. Table [2](#add14944-tbl-0002){ref-type="table"} lists the estimated pooled mean antibody prevalence among PWID across MENA. The country‐specific estimate ranged from 21.7% (95% CI = 4.9--38.6%) in Tunisia to 94.2% (95% CI = 90.8--96.7%) in Libya. Egypt, Iran, Libya, Morocco, Pakistan and Saudi Arabia had a prevalence estimate \> 50%. The pooled mean for MENA as a whole was 49.3% (95% CI = 44.4--54.1%).

###### 

Results of the meta‐analyses of hepatitis C virus (HCV) antibody prevalence measures among people who inject drugs (PWID) across the Middle East and North Africa (MENA).

  Country        Studies   Samples   HCV antibody prevalence   Pooled HCV antibody prevalence   Heterogeneity measures                        Population size \[32--42\]   Estimated number of HCV antibody‐positive current PWID   Estimated number of HCV chronically infected current PWID^g^                                                                            
  -------------- --------- --------- ------------------------- -------------------------------- --------------------------------------------- ---------------------------- -------------------------------------------------------- -------------------------------------------------------------- ------------ ------------------------------ ---------------------------- ----------------------------
  Afghanistan    17        8597      36.0                      9.5--70.0                        32.9                                          25.2--41.1                   711.6 (*P* \< 0.01)                                      97.8% (97.2--98.2%)                                            4.9--70.4    18 820 (12 435--23 000)        6192 (3134--9453)            4360 (2207--6657)
  Algeria        0         --        --                        --                               --                                            --                           --                                                       --                                                             --           40 961 (26 333--55 590)        20 194 (11 692--30 074)^f^   14 220 (8233--21 178)
  Bahrain        0         --        --                        --                               --                                            --                           --                                                       --                                                             --           1937 (1369--15 506)            955 (608--8388)^f^           672 (428--5907)
  Djibouti       0         --        --                        --                               --                                            --                           --                                                       --                                                             --           821 (616--1026)                405 (273--555)^f^            285 (193--391)
  Egypt          2         243       51.8                      40.6--63.0                       51.6[d](#add14944-note-0008){ref-type="fn"}   30.0--73.0                   --                                                       --                                                             --           90 809 (71 485--119 633)       46 857 (21 446--87 332)      32 997 (15 102--61 499)
  Iran           60        19 614    52.0                      11.3--88.9                       52.6                                          47.6--57.5                   2716.0 (*P* \< 0.01)                                     97.9% (97.6--98.1%)                                            17.0--86.7   185 000 (135 000--300 000)     97 310 (64 260--172 500)     68 526 (45 252--121 475)
  Iraq           0         --        --                        --                               --                                            --                           --                                                       --                                                             --           34 673 (23 115--46 230)        17 094 (10 263--25 010)^f^   12 037 (7227--17 612)
  Jordan         0         --        --                        --                               --                                            --                           --                                                       --                                                             --           4850 (3200--6500)              2391 (1421--3517)^f^         1684 (1001--2476)
  Kuwait         0         --        --                        --                               --                                            --                           --                                                       --                                                             --           4050 (1850--8750)              1997 (821--4734)^f^          1406 (578--3334)
  Lebanon        3         240       23.4                      5.0--52.8                        25.0                                          4.4--54.5                    42.6 (*P* \< 0.01)                                       95.3% (89.6--97.9%)                                            0.0--100     3207 (1506--4908)              802 (66--2675)               565 (47--1884)
  Libya          1         328       94.2                      94.2                             94.2[e](#add14944-note-0007){ref-type="fn"}   90.8--96.7                   --                                                       --                                                             --           4446 (2948--5943)              4188 (2677--5747)            2949 (1885--4047)
  Mauritania     0         --        --                        --                               --                                            --                           --                                                       --                                                             --           6908 (5181--8635)              3406 (2300--4672)^f^         2398 (1620--3290)
  Morocco        3         759       46.2                      40.9--71.9                       53.0                                          33.1--72.4                   63.6 (*P* \< 0.01)                                       96.9% (93.6--98.5%)                                            0.0--100     18 000 (13 500--22 500)        9540 (4469--16 290)          6718 (3147--11 471)
  Oman           1         512       48.1                      48.1                             48.1[e](#add14944-note-0007){ref-type="fn"}   43.8--52.4                   --                                                       --                                                             --           4250 (2800--5700)              2044 (1226--2987)            1440 (864--2103)
  Pakistan       19        3304      55.0                      8.0--93.8                        56.2                                          41.4--70.1                   1297.1 (*P* \< 0.01)                                     98.6% (98.3--98.8%)                                            1.6--100     117 632 (89 500--510 000)      66 109 (32 399--239 700)     46 554 (22 815--168 797)
  Palestine      4         480       41.4                      33.7--47.6                       41.6                                          36.2--47.0                   4.3 (*P* = 0.23)                                         29.8% (0.0--74.4%)                                             24.9--59.3   1850 (1200--2500)              770 (497--1753)              542 (350--1234)
  Qatar          0         --        --                        --                               --                                            --                           --                                                       --                                                             --           1190 (780--1600)               587 (346--866)^f^            413 (244--610)
  Saudi Arabia   5         12 298    69.0                      14.4--77.8                       55.5                                          20.5--87.6                   3674.4 (*P* \< 0.01)                                     99.9% (99.9--99.9%)                                            0.0--100.0   16 800 (11 336--22 264)        9324 (2324--19 503)          6566 (1636--13 734)
  Somalia        0         --        --                        --                               --                                            --                           --                                                       --                                                             --           1000 (750--1250)               493 (53--676)^f^             347 (37--476)
  Sudan          0         --        --                        --                               --                                            --                           --                                                       --                                                             --           37 828 (24 319--51 337)        18 649 (10 798--27 773)^f^   13 133 (7604--19 558)
  Syria          2         95        40.8                      12.0--23.0                       39.6[d](#add14944-note-0008){ref-type="fn"}   7.0--78.5                    --                                                       --                                                             --           8000 (5750--10 250)            3168 (403--8046)             2231 (283--3738)
  Tunisia        1         23        21.7                      21.7                             21.7[e](#add14944-note-0007){ref-type="fn"}   4.9--38.6                    --                                                       --                                                             --           11 000 (8462--13 750)          2387 (415--5308)             1681 (292--3738)
  UAE            0         --        --                        --                               --                                            --                           --                                                       --                                                             --           4800 (3200--6400)              2366 (1421--3462)^f^         1666 (1001--2438)
  Yemen          0         --        --                        --                               --                                            --                           --                                                       --                                                             --           19 770 (12710--26 830)         9747 (5643--14 515)^f^       6864 (3974--10 221)
  MENA           118       46 493    45.5                      5.0--94.4                        49.3                                          44.4--54.1                   12 232.4 (*P* \< 0.01)                                   99.1% (99.0--99.1%)                                            6.0--93.3    638 602 (459 345--1 270 101)   314 831 (203 949--687 125)   221 704 (143 621--483 873)

CI = confidence interval; UAE = United Arab Emirates.

Q = Cochran Q statistic assessing the existence of heterogeneity in HCV antibody prevalence estimates.

*I* ^2^ = a measure assessing the magnitude of between‐study variation that is due to true differences in HCV antibody prevalence estimates across studies rather than chance.

Prediction interval: a measure estimating the 95% interval in which the true HCV antibody prevalence in a new study will lie.

Weighted average calculated as too few studies were available (\< 3) to perform a meta‐analysis.

The mean is reflective of the point study in the only study that is available.

For countries with no data available, the regional pooled mean HCV antibody prevalence estimate was used to estimate the number of HCV antibody‐positive current PWID.

Confidence intervals were calculated based on the uncertainty intervals of the population size and the confidence intervals of the pooled mean HCV antibody prevalence estimate.

Evidence for heterogeneity in HCV antibody prevalence was observed in the majority of meta‐analyses (*P* \< 0.01; Table [2](#add14944-tbl-0002){ref-type="table"}). Most of the variation in prevalence was due to true variation in prevalence across studies rather than sampling variation (*I* ^2^ was most often \> 90%; Table [2](#add14944-tbl-0002){ref-type="table"}). This was also confirmed by the wide prediction intervals (Table [2](#add14944-tbl-0002){ref-type="table"}).

Estimated number of infections among PWID {#add14944-sec-0015}
-----------------------------------------

Based on a total of seven identified studies (Supporting information, Table [S2](#add14944-supitem-0001){ref-type="supplementary-material"}), the pooled mean viremic rate was 70.4% (95% CI = 53.7--84.9%). This estimate was used in calculating the number of chronic infections for each country and for MENA as a whole.

Table [2](#add14944-tbl-0002){ref-type="table"} lists the estimated number of HCV antibody‐positive PWID and the estimated number of chronically infected PWID in each country and in MENA as a whole. The largest number of chronically infected PWID was found in Iran at 68 526, followed by Pakistan at 46 554 and Egypt at 32 997. The remaining countries had a substantially smaller number of chronically infected PWID. In MENA as a whole, 314 831 PWID were estimated to be antibody‐positive and 221 704 PWID were estimated to be chronically infected.

HCV antibody prevalence predictors, trends and sources of between‐study heterogeneity {#add14944-sec-0016}
-------------------------------------------------------------------------------------

Table [3](#add14944-tbl-0003){ref-type="table"} lists the results of the univariable and multivariable meta‐regressions. The variables country, study site and year of data collection were found to be statistically significant predictors (*P* \< 0.2), and were therefore included in the final multivariable analysis.

###### 

Univariable and multivariable meta‐regression models for hepatitis C virus (HCV) antibody prevalence in people who inject drugs (PWID) across the Middle East and North Africa (MENA).

                                                                            Univariable analysis                    Multivariable analysis^a^                                              
  ------------------------- ----------------------------------------------- ---------------------- ---------------- --------------------------- ------- ---------------- ----------------- -------
  Country                   Afghanistan                                     17                     1                --                                                   1                 --
  Iran                      60                                              2.4 (1.3--4.2)         0.004                                                2.5 (0.8--7.8)   0.109             
                            Pakistan                                        19                     2.8 (1.4--5.8)   0.005                                                5.0 (1.4--18.0)   0.014
                            Palestine                                       4                      1.5 (0.4--4.8)   0.525                                                1.5 (0.4--5.2)    0.531
                            Saudi Arabia                                    5                      2.6 (0.9--7.7)   0.084                                                3.5 (0.8--15.8)   0.109
                            Others[a](#add14944-note-0013){ref-type="fn"}   13                     1.7 (0.8--3.8)   0.173                       0.054   5.1              2.0 (0.7--5.2)    0.170
  Study site                Community                                       14                     1                --                                                   1                 --
                            Clinical setting                                24                     0.8 (0.4--1.7)   0.580                                                1.2 (0.5--2.7)    0.713
                            Drop‐in or rehabilitation center                26                     0.9 (0.4--1.8)   0.787                                                1.4 (0.6--3.4)    0.438
                            VCT                                             7                      0.4 (0.2--1.1)   0.086                                                1.8 (0.4--8.3)    0.478
                            Prison                                          19                     1.7 (0.8--3.5)   0.173                                                2.6 (1.0--6.7)    0.041
                            Not specified                                   25                     0.6 (0.3--1.3)   0.223                       0.034   6.3              1.9 (0.6--5.7)    0.269
  Year of data collection                                                   118                    1.0 (0.9--1.0)   0.188                       0.188   0.6              1.0 (0.9--1.0)    0.643
  Year of publication                                                       118                    1.0 (0.9--1.0)   0.434                       0.434   0.0              --                --
  Sample size               \< 100                                          34                     1                --                                                   --                --
  ≥ 100                     84                                              1.1 (0.7--1.7)         0.702            0.702                       0.0     --               --                
  Sampling method           Non‐probability‐based                           91                     1                --                                                   --                --
                            Probability‐based                               27                     0.9 (0.5--1.4)   0.525                       0.525   0.0              --                --

Adj=adjusted; CI = confidence interval; LR = likelihood ratio; OR = odds ratio; aOR = adjusted odds ratio; VCT = voluntary counselling and testing.

The adjusted *R*‐squared for the full model was 7.7%.

Countries with three or fewer studies (Egypt, Lebanon, Libya, Morocco, Oman, Syria and Tunisia) were combined into the 'Others' category.

In the multivariable analysis, year of data collection lost significance (*P* \> 0.05): here, only country and study site remained statistically significant. Pakistan had a statistically significant higher HCV antibody prevalence among PWID than in Afghanistan; the adjusted OR was 5.0 (95% CI = 1.4--18.0). Prison study site had a statistically significant higher antibody prevalence among PWID than in the community; the adjusted OR was 2.6 (95% CI = 1.0--6.7)

Notably, no small‐study effect, i.e. studies with smaller sample size yielding different antibody prevalence, [139](#add14944-bib-0138){ref-type="ref"} was found. Similarly, the sampling method had no effect on observed antibody prevalence. The model explained 7.7% of the variability in antibody prevalence.

Separate meta‐regressions were performed for Afghanistan, Iran and Pakistan (countries with ≥ 15 studies), all of which showed no statistically significant evidence for a declining or increasing trend in antibody prevalence over time.

A sensitivity analysis was performed using only the non‐imputed observations to assess the impact of the imputation on the results, and the results confirmed the results of the original meta‐regression.

Genotype proportions and diversity {#add14944-sec-0017}
----------------------------------

Table [4](#add14944-tbl-0004){ref-type="table"} lists the frequency of each HCV genotype as well as its pooled mean proportion estimate. The pooled mean proportion (expressed as a percentage) was 42.7% (95% CI = 31.7--54.0%) for genotype 3, 35.9% (95% CI = 23.5--49.1%) for genotype 1, 4.1% (95% CI = 0.1--11.7%) for genotype 4, 0.5% (95% CI = 0.0--4.2%) for genotype 2 and 0.0% (95% CI = 0.0--0.0%) for genotype 5. Genotypes 6 and 7 were not found (among PWID) in any of the available studies. Genotype diversity was moderate for MENA as a whole (Shannon Diversity Index = 1.01 out of 1.95; 52.1%). Most PWID were infected by a single genotype: only 2.1% of them were coinfected by multiple genotypes.

###### 

Frequency and pooled mean proportion for each hepatitis C virus (HCV) genotype across the Middle East and North Africa (MENA).

  Genotype     Studies   Samples       Percentage (actual studies)   Percentage (meta‐analysis)   Heterogeneity measures                                                            
  ------------ --------- ------------- ----------------------------- ---------------------------- ------------------------ ------------ --------------------- --------------------- -----------
  Genotype 1   15        449 (46.3%)   41.7                          0.0--64.9                    35.9                     23.5--49.1   163.5 (*P* \< 0.01)   91.4% (87.6--94.1%)   0.1--85.9
  Genotype 2   15        48 (5.0%)     0.0                           0.0--41.5                    0.5                      0.0--4.2     85.2 (*P* \< 0.01)    83.6% (74.2--89.5%)   0.0--23.4
  Genotype 3   15        422 (43.6%)   50.0                          0.0--100                     42.7                     31.7--54.0   114.0 (*P* \< 0.01)   87.7% (81.4--91.9%)   6.2--83.9
  Genotype 4   15        47 (4.9%)     27.4                          0.0--75.0                    4.1                      0.1--11.7    144.0 (*P* \< 0.01)   90.3% (85.7--93.4%)   0.0--44.7
  Genotype 5   15        3 (0.3%)      0.0                           0.0--2.9                     0.0                      0.0--0.0     9.9 (*P* = 0.77)      0.0% (0.0--0.0%)      0.0--0.0

CI = confidence interval.

Q = Cochran Q statistic assessing the existence of heterogeneity in HCV genotype proportion estimates.

*I* ^2^ = A measure assessing the magnitude of between‐study variation that is due to true differences in HCV genotype proportion estimates across studies rather than chance.

Prediction interval = estimates the 95% interval in which the true HCV genotype proportion estimate in a new HCV genotype study will lie.

Discussion {#add14944-sec-0018}
==========

We have presented a comprehensive characterization of HCV epidemiology among PWID in MENA. Generally, we found very high HCV antibody prevalence among PWID, which varied by country. Approximately half (49.3%) of PWID have ever been infected with HCV, with more than two‐thirds (70.4%) of those ever being infected being chronically infected---findings that are similar to the global epidemiology of HCV in PWID [8](#add14944-bib-0008){ref-type="ref"}, [31](#add14944-bib-0031){ref-type="ref"}. The variables country (Pakistan, with an OR of 5.0) and study site (prison, with an OR of 2.6) were identified as statistically significant predictors of higher antibody prevalence; there was no evidence that sampling method or sample size affected the observed prevalence. No evidence was also found for any change in antibody prevalence over time. Moderate genotype diversity was observed in MENA as a whole. The pooled mean percentages of genotypes were highest in genotype 3 (42.7%), followed by genotype 1 (35.9%).

We estimated that there are approximately 221 000 chronically infected PWID in MENA (Table [2](#add14944-tbl-0002){ref-type="table"}). As this estimate is only for those currently injecting, this number represents the lower bound for the number of chronically infected people who acquired HCV through injecting drug use in this region. As available studies normally investigate PWID who are currently injecting, we are unable to estimate the number of chronic infections among ex‐PWID, people who injected drugs in the past, but are no longer injecting at present. In the United States, for example, the number of HCV‐infected ex‐PWID was found to be sevenfold higher than that of HCV‐infected current PWID. [140](#add14944-bib-0139){ref-type="ref"} Therefore, the number of chronic infections due to injecting drug use in MENA could be substantially greater than the estimated 221 000 for current PWID, although probably not sevenfold higher as it is in the United States, as injecting drug use in this region appears to be more of a recent phenomenon compared to the United States [2](#add14944-bib-0002){ref-type="ref"}, [32](#add14944-bib-0032){ref-type="ref"}.

The identified very high HCV antibody prevalence, at 49% (Table [2](#add14944-tbl-0002){ref-type="table"}), among PWID indicates that there is high epidemic potential for concentrated HIV epidemics. A recent mathematical modeling study, [141](#add14944-bib-0140){ref-type="ref"} as well as ecological analyses [32](#add14944-bib-0032){ref-type="ref"}, [142](#add14944-bib-0141){ref-type="ref"}, suggest that an antibody prevalence level \> 45% indicates an epidemic potential for sustainable and concentrated HIV epidemics. Indeed, reviews of the HIV epidemic among PWID in MENA [9](#add14944-bib-0009){ref-type="ref"}, [23](#add14944-bib-0023){ref-type="ref"}, [24](#add14944-bib-0024){ref-type="ref"}, [32](#add14944-bib-0032){ref-type="ref"}, [143](#add14944-bib-0142){ref-type="ref"}, as well as modeling estimates [144](#add14944-bib-0143){ref-type="ref"}, [145](#add14944-bib-0144){ref-type="ref"}, [146](#add14944-bib-0145){ref-type="ref"}, indicate emerging HIV epidemics with often high levels of infection incidence.

HCV antibody prevalence in PWID varied throughout, and within, countries (Table [1](#add14944-tbl-0001){ref-type="table"}). In Afghanistan, for example, antibody prevalence showed subnational variation [18](#add14944-bib-0018){ref-type="ref"}. This variability may be reflective of variation in the local injecting environment, impact of expansion of harm reduction services [147](#add14944-bib-0146){ref-type="ref"} or the natural HCV epidemic dynamics among recently formed injecting networks.

Variations in antibody prevalence across MENA may also be attributed to differences in the typologies of the PWID populations and nature of their social and injecting networks [23](#add14944-bib-0023){ref-type="ref"}, [148](#add14944-bib-0147){ref-type="ref"}. For example, in Lebanon, where antibody prevalence was on the lower range of that observed in MENA, PWID appear to form closed small networks, with most injecting occurring in private residences and among friends [2](#add14944-bib-0002){ref-type="ref"}, [32](#add14944-bib-0032){ref-type="ref"}, [149](#add14944-bib-0148){ref-type="ref"}, and thus not conducive for HCV (or HIV) transmission. In contrast, in Iran and Pakistan, where antibody prevalence was in the higher range of that observed in MENA, PWID networks appear to be well connected, with instances of injecting occurring among individuals not necessarily socially related, such as in shooting galleries [2](#add14944-bib-0002){ref-type="ref"}, [32](#add14944-bib-0032){ref-type="ref"}, [148](#add14944-bib-0147){ref-type="ref"}, [150](#add14944-bib-0149){ref-type="ref"}, and thus conducive for infection transmission. In Pakistan, specifically, much of the injecting appears to occur in public places among groups, and with the reported use of professional injectors or 'street doctors', who frequently re‐use injecting equipment [2](#add14944-bib-0002){ref-type="ref"}, [32](#add14944-bib-0032){ref-type="ref"}, [151](#add14944-bib-0150){ref-type="ref"}, [152](#add14944-bib-0151){ref-type="ref"}, [153](#add14944-bib-0152){ref-type="ref"}, [154](#add14944-bib-0153){ref-type="ref"}, [155](#add14944-bib-0154){ref-type="ref"}.

Our results suggest that prisons are a setting predictive of higher HCV antibody prevalence (Table [3](#add14944-tbl-0003){ref-type="table"}), possibly because of higher‐risk injecting in prisons, or that this setting tends to be frequented with higher‐risk PWID. Other evidence supports this conjecture, and indicated an important role for incarceration in the dynamics of HCV and HIV transmission in MENA [9](#add14944-bib-0009){ref-type="ref"}, [23](#add14944-bib-0023){ref-type="ref"}, [156](#add14944-bib-0155){ref-type="ref"}, [157](#add14944-bib-0156){ref-type="ref"}. This highlights the need for harm reduction and HCV/HIV testing and treatment services in prisons.

Genotype 3 was found to be the major circulating strain among PWID (Table [4](#add14944-tbl-0004){ref-type="table"}), in concordance with the global association between injecting drug use and this genotype [158](#add14944-bib-0157){ref-type="ref"}. This finding, however, also reflects the fact that genotype 3 is the dominant circulating strain in Afghanistan[18](#add14944-bib-0018){ref-type="ref"}, [159](#add14944-bib-0158){ref-type="ref"} and Pakistan [19](#add14944-bib-0019){ref-type="ref"}, [159](#add14944-bib-0158){ref-type="ref"}, [160](#add14944-bib-0159){ref-type="ref"}, also with a large presence in Iran [14](#add14944-bib-0014){ref-type="ref"}, [159](#add14944-bib-0158){ref-type="ref"}, countries that contributed most of the genotype studies.

Despite the observed high burden of HCV and the emerging and, at times, large HIV epidemics among PWID in MENA [9](#add14944-bib-0009){ref-type="ref"}, [23](#add14944-bib-0023){ref-type="ref"}, [24](#add14944-bib-0024){ref-type="ref"}, [32](#add14944-bib-0032){ref-type="ref"}, [143](#add14944-bib-0142){ref-type="ref"}, [144](#add14944-bib-0143){ref-type="ref"}, harm reduction services remain overall limited or essentially non‐existent across countries, hindered by poor availability, quality and coverage of services, stigma, fear of legal prosecution, ineffective governance, limited resources and competing national priorities. By 2016, needle and syringe exchange programs (NSPs) were available only in 10 countries of the region, and opioid substitution therapy (OST) in only five [161](#add14944-bib-0160){ref-type="ref"}. Such programs, when they attain high coverage, have proved successful in reducing both HCV and HIV incidence in other regions [162](#add14944-bib-0161){ref-type="ref"}, [163](#add14944-bib-0162){ref-type="ref"}, [164](#add14944-bib-0163){ref-type="ref"}.

Within the socio‐cultural and politico‐legal context of the region, and with the overall reluctance of political leaders to acknowledge and deal with most affected communities, harm reduction in MENA is still the realm of non‐governmental organizations (NGOs). Experience in several countries such as Morocco, Iran, and Lebanon, among others, has proved that this is a successful and feasible model to access and reach hard‐to‐reach communities such as PWID [23](#add14944-bib-0023){ref-type="ref"}, [165](#add14944-bib-0164){ref-type="ref"}. Scale‐up of harm reduction and further integration of NGO services within national policies are needed to strengthen the response to the high burden of HCV and the growing burden of HIV among PWID in MENA. Recent evidence has emphasized the effectiveness of HCV DAA treatment as prevention (HCV‐TasP) in achieving HCV elimination by 2030 [166](#add14944-bib-0165){ref-type="ref"}, [167](#add14944-bib-0166){ref-type="ref"}, even in countries with very large epidemics such as Egypt and Pakistan [12](#add14944-bib-0012){ref-type="ref"}, [13](#add14944-bib-0013){ref-type="ref"}, [19](#add14944-bib-0019){ref-type="ref"}, [160](#add14944-bib-0159){ref-type="ref"}, [167](#add14944-bib-0166){ref-type="ref"}, [168](#add14944-bib-0167){ref-type="ref"}. Essentially, HCV‐TasP effectively reduces the pool of HCV chronically infected individuals, thereby curtailing the onward transmission of the infection. Several countries, most prominently Egypt [169](#add14944-bib-0168){ref-type="ref"}, [170](#add14944-bib-0169){ref-type="ref"}, have initiated and implemented ambitious and large DAA treatment programs to achieve elimination [171](#add14944-bib-0170){ref-type="ref"}. Evidence has highlighted the potency of combining HCV‐TasP, which reduces the prevalence of chronic infection and onward transmission, with harm reduction services, such as NSP and OST programs, which reduce HCV incidence [167](#add14944-bib-0166){ref-type="ref"}, [172](#add14944-bib-0171){ref-type="ref"}. Integrating HCV testing and treatment in harm reduction services is integral to overcoming difficulties in accessing PWID for HCV interventions and to effectively reduce the number of chronically infected PWID.

A review of HCV, HBV and HIV among PWID globally has been recently published, in which the reported HCV antibody prevalence among PWID (48.1%) was similar to that found in this study (49.3%) [8](#add14944-bib-0008){ref-type="ref"}. However, as a consequence of our comprehensive systematic approach, including searches of national journals and databases and the gray literature, this study identified more data for MENA, covered more countries for this region, analytically examined trends and associations and reported more outcome measures and analyses (such as for genotype distribution).

This study identified key gaps in the epidemiological evidence for HCV infection among PWID in MENA. Evidence varied substantially by country, with no studies identified for 12 of the 24 MENA countries (Table [1](#add14944-tbl-0001){ref-type="table"}). Several countries that reported high HCV antibody prevalence also had too few available studies, such as for Libya, with only one identified study (of high quality), but at a very high antibody prevalence of 94.2% [110](#add14944-bib-0109){ref-type="ref"}. Some studies were limited to a single metropolitan area or study site, and therefore may not be representative of the wider PWID population in the country. Indeed, from countries where there was a high number of studies, such as Iran (Table [1](#add14944-tbl-0001){ref-type="table"}), there was wide variation in antibody prevalence, suggesting the possibility of bias in estimating country‐specific antibody prevalence for countries with too few studies.

Only seven studies reported HCV RNA among antibody‐positive PWID. Accordingly, the estimated viremic rate may not be representative of the wider PWID population in the region. However, a systematic meta‐analysis of viremic rates in different populations in MENA arrived at similar values for the viremic rate, irrespective of subregion or population [30](#add14944-bib-0030){ref-type="ref"}. Similar values were also reached in the probability‐based and nationally representative surveys in Egypt [173](#add14944-bib-0172){ref-type="ref"}, [174](#add14944-bib-0173){ref-type="ref"}, in the National Health and Nutrition Examination Surveys in the United States [175](#add14944-bib-0174){ref-type="ref"} and in other population‐based surveys such as in India [176](#add14944-bib-0175){ref-type="ref"}, Ireland [177](#add14944-bib-0176){ref-type="ref"} and Latvia [178](#add14944-bib-0177){ref-type="ref"}.

Only 15 studies reported HCV genotypes among PWID, and therefore available genotype data may not have captured the true genotype distribution and diversity in PWID. For example, the HCV epidemic in Egypt [12](#add14944-bib-0012){ref-type="ref"}, [13](#add14944-bib-0013){ref-type="ref"}, [167](#add14944-bib-0166){ref-type="ref"}, the largest in MENA, is very dominated by genotype 4 [159](#add14944-bib-0158){ref-type="ref"}, but there were few studies from Egypt for PWID, thus possibly underestimating the frequency of this genotype in all of PWID in MENA.

Most studies employed non‐probability‐based sampling; however, the results of the meta‐regression indicated that this had no discernable effect on observed HCV antibody prevalence (Table [3](#add14944-tbl-0003){ref-type="table"})---this may not have limited the representativeness of these studies. High heterogeneity in antibody prevalence was observed (Table [2](#add14944-tbl-0002){ref-type="table"}), but most of it remained unexplained by the considered factors in the meta‐regressions (Table [3](#add14944-tbl-0003){ref-type="table"}). As indicated above, we were unable to assess the number of chronically infected ex‐PWID, as available studies investigated only current PWID---our estimate for the number of chronically infected PWID represents the lower bound.

Despite these limitations, we were able to identify a substantial volume of evidence on HCV infection in PWID in MENA, which facilitated diverse analyses leading to informative inferences. However, further research is needed to address the gaps in evidence. Expanding existing surveillance systems and conducting repeated integrated bio‐behavioral surveillance (IBBS) surveys for HCV (and HIV) in PWID is critical in delineating HCV epidemiology in this population in countries with limited or no data [2](#add14944-bib-0002){ref-type="ref"}, [143](#add14944-bib-0142){ref-type="ref"}, [179](#add14944-bib-0178){ref-type="ref"}. These surveys need also to have a wider geographic coverage with multi‐sites included, and must incorporate innovative sampling methodologies, such as respondent‐driven sampling or time‐location sampling, to reach PWID populations. PWID size estimation studies and mapping is also critical in delineating the typologies of PWID injecting and sexual networks [32](#add14944-bib-0032){ref-type="ref"}. More studies of HCV viremic rate are also warranted, especially so that the viremic rate could be used to monitor the progress in scaling‐up HCV treatment [30](#add14944-bib-0030){ref-type="ref"}. Addressing these gaps is critical to inform the expansion of harm reduction services and testing and treatment programs.

Conclusion {#add14944-sec-0019}
==========

Our findings indicated high HCV antibody prevalence among PWID in MENA, approximately half of whom have ever been infected with this infection and one‐third are chronically infected. There was no evidence for any decline in antibody prevalence in recent years. Most infections among PWID were either by genotypes 3 or 1. In addition to 221 000 chronically infected current PWID, there is an unknown number of ex‐PWID who may have acquired the infection during their past injecting drug use.

The evidence collectively, and overwhelmingly, attests to the immediate need for a robust response to the epidemic among PWID. The lack of evidence of a decline in antibody prevalence and the high viremic rate emphasize that interventions are either non‐existent or have not reached sufficient effectiveness, coverage and/or quality to impact the epidemiology. Without an appropriate response, elimination of HCV by 2030 may not be possible. Harm reduction and testing and treatment services must be expanded in the wider PWID community as well as in prisons, and innovative strategies need to be employed to ensure accessibility to HCV testing and treatment and to offset decades of stigma and criminalization of this population.
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